News
BOLT
3.990
-1.48%
-0.060
Weekly Report: what happened at BOLT last week (0803-0807)?
Weekly Report · 1d ago
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates
NASDAQ · 4d ago
Weekly Report: what happened at BOLT last week (0727-0731)?
Weekly Report · 08/03 09:26
Repligen (RGEN) Beats Q2 Earnings and Revenue Estimates
NASDAQ · 07/28 12:15
Weekly Report: what happened at BOLT last week (0720-0724)?
Weekly Report · 07/27 09:27
Weekly Report: what happened at BOLT last week (0713-0717)?
Weekly Report · 07/20 09:26
Weekly Report: what happened at BOLT last week (0706-0710)?
Weekly Report · 07/13 09:27
Weekly Report: what happened at BOLT last week (0629-0703)?
Weekly Report · 07/06 09:28
Weekly Report: what happened at BOLT last week (0622-0626)?
Weekly Report · 06/29 09:26
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST), Revolution Medicines (RVMD) and Bolt Biotherapeutics (BOLT)
TipRanks · 06/25 12:00
Weekly Report: what happened at BOLT last week (0615-0619)?
Weekly Report · 06/22 09:30
Weekly Report: what happened at BOLT last week (0608-0612)?
Weekly Report · 06/15 09:30
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting
TipRanks · 06/11 21:11
Weekly Report: what happened at BOLT last week (0601-0605)?
Weekly Report · 06/08 09:28
Weekly Report: what happened at BOLT last week (0525-0529)?
Weekly Report · 06/01 09:30
Bolt Biotherapeutics Initiated at Buy by Rodman & Renshaw
Dow Jones · 05/29 12:43
Bolt Biotherapeutics Price Target Announced at $22.00/Share by Rodman & Renshaw
Dow Jones · 05/29 12:43
Rodman & Renshaw Initiates Coverage On Bolt Biotherapeutics with Buy Rating, Announces Price Target of $22
Benzinga · 05/29 12:33
Bolt Biotherapeutics initiated with a Buy at Rodman & Renshaw
TipRanks · 05/28 20:58
Weekly Report: what happened at BOLT last week (0518-0522)?
Weekly Report · 05/25 09:31
More
Webull provides a variety of real-time BOLT stock news. You can receive the latest news about Bolt Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.